Cargando…

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)

PURPOSE: To explore the value of radiotherapy in C-SCLC patients, especially in those receiving a radical resection. RESULTS: The differences of survivals between the postoperative radiotherapy (PORT) and non-PORT groups were not statistically significant. But analyzing the benefits in subgroups, PO...

Descripción completa

Detalles Bibliográficos
Autores principales: Men, Yu, Luo, Yang, Zhai, Yirui, Liang, Jun, Feng, Qinfu, Chen, Dongfu, Xiao, Zefen, Zhou, Zongmei, Hui, Zhouguang, Wang, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564736/
https://www.ncbi.nlm.nih.gov/pubmed/28430661
http://dx.doi.org/10.18632/oncotarget.16885
_version_ 1783258291378323456
author Men, Yu
Luo, Yang
Zhai, Yirui
Liang, Jun
Feng, Qinfu
Chen, Dongfu
Xiao, Zefen
Zhou, Zongmei
Hui, Zhouguang
Wang, Luhua
author_facet Men, Yu
Luo, Yang
Zhai, Yirui
Liang, Jun
Feng, Qinfu
Chen, Dongfu
Xiao, Zefen
Zhou, Zongmei
Hui, Zhouguang
Wang, Luhua
author_sort Men, Yu
collection PubMed
description PURPOSE: To explore the value of radiotherapy in C-SCLC patients, especially in those receiving a radical resection. RESULTS: The differences of survivals between the postoperative radiotherapy (PORT) and non-PORT groups were not statistically significant. But analyzing the benefits in subgroups, PORT significantly improved OS (p = 0.015), DFS (p = 0.026), LRFS (p = 0.008) and DMFS (p = 0.030) in stage III patients. For the patients with N2 stage, all survivals of the PORT group were also statistically significantly higher than non-PORT group (p = 0.018, 0.032, 0.008, 0.042). Patients with more than 10% of metastatic lymph nodes could get a significant benefit survivals by receiving PORT (p = 0.033, 0.030, 0.025, 0.031). Having a systematic dissection of more than 17 lymph nodes was a subset which could get better OS and LRFS by receiving PORT (p = 0.045, 0.048). METHODS: Between Jan. 2004 to Dec. 2012, fifty-five patients diagnosed as C-SCLC after complete surgical resection in our center were retrospectively analyzed. The overall survival (OS), disease free survival (DFS), loco-regional recurrence free survival (LRFS), and distant metastasis free survival (DMFS) were calculated by Kaplan-Meier method. CONCLUSIONS: PORT can significantly improve the survival of C-SCLC patients with resected pathological pN2 stage. For the patients with a large percent of metastatic lymph nodes, PORT can also improve survivals.
format Online
Article
Text
id pubmed-5564736
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55647362017-08-23 The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC) Men, Yu Luo, Yang Zhai, Yirui Liang, Jun Feng, Qinfu Chen, Dongfu Xiao, Zefen Zhou, Zongmei Hui, Zhouguang Wang, Luhua Oncotarget Research Paper PURPOSE: To explore the value of radiotherapy in C-SCLC patients, especially in those receiving a radical resection. RESULTS: The differences of survivals between the postoperative radiotherapy (PORT) and non-PORT groups were not statistically significant. But analyzing the benefits in subgroups, PORT significantly improved OS (p = 0.015), DFS (p = 0.026), LRFS (p = 0.008) and DMFS (p = 0.030) in stage III patients. For the patients with N2 stage, all survivals of the PORT group were also statistically significantly higher than non-PORT group (p = 0.018, 0.032, 0.008, 0.042). Patients with more than 10% of metastatic lymph nodes could get a significant benefit survivals by receiving PORT (p = 0.033, 0.030, 0.025, 0.031). Having a systematic dissection of more than 17 lymph nodes was a subset which could get better OS and LRFS by receiving PORT (p = 0.045, 0.048). METHODS: Between Jan. 2004 to Dec. 2012, fifty-five patients diagnosed as C-SCLC after complete surgical resection in our center were retrospectively analyzed. The overall survival (OS), disease free survival (DFS), loco-regional recurrence free survival (LRFS), and distant metastasis free survival (DMFS) were calculated by Kaplan-Meier method. CONCLUSIONS: PORT can significantly improve the survival of C-SCLC patients with resected pathological pN2 stage. For the patients with a large percent of metastatic lymph nodes, PORT can also improve survivals. Impact Journals LLC 2017-04-06 /pmc/articles/PMC5564736/ /pubmed/28430661 http://dx.doi.org/10.18632/oncotarget.16885 Text en Copyright: © 2017 Men et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Men, Yu
Luo, Yang
Zhai, Yirui
Liang, Jun
Feng, Qinfu
Chen, Dongfu
Xiao, Zefen
Zhou, Zongmei
Hui, Zhouguang
Wang, Luhua
The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
title The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
title_full The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
title_fullStr The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
title_full_unstemmed The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
title_short The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
title_sort role of postoperative radiotherapy (port) in combined small cell lung cancer (c-sclc)
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564736/
https://www.ncbi.nlm.nih.gov/pubmed/28430661
http://dx.doi.org/10.18632/oncotarget.16885
work_keys_str_mv AT menyu theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT luoyang theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT zhaiyirui theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT liangjun theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT fengqinfu theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT chendongfu theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT xiaozefen theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT zhouzongmei theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT huizhouguang theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT wangluhua theroleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT menyu roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT luoyang roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT zhaiyirui roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT liangjun roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT fengqinfu roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT chendongfu roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT xiaozefen roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT zhouzongmei roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT huizhouguang roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc
AT wangluhua roleofpostoperativeradiotherapyportincombinedsmallcelllungcancercsclc